Autophagy is involved in a clearance of anti-cancer agent doxorubicin in the multidrug resistant cancer cell line.
Project/Area Number |
25670083
|
Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
Allocation Type | Multi-year Fund |
Research Field |
Medical pharmacy
|
Research Institution | Nagahama Institute of Bio-Science and Technology |
Principal Investigator |
NARA Atsuki 長浜バイオ大学, バイオサイエンス学部, 講師 (60387959)
|
Project Period (FY) |
2013-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Keywords | 薬剤耐性 / オートファジー / ドキソルビシン / 抗がん剤排除 |
Outline of Final Research Achievements |
Release of drug from the cancer cells contributes reduction of its cytotoxicity. How are the chemotherapeutic agents that accumulated in the cells released to the extracellular space? In my study, I tried to examine about a direct involvement of autophagy in anti-cancer drug doxorubicin delivery. The study provides a novel insight for an autophagic delivery of doxorubicin from the nucleus to the lysosomes in multidrug resistant cancer cell line.
|
Report
(3 results)
Research Products
(3 results)